Acumen Pharmaceuticals, Inc. Shareholders' Equity
Acumen Pharmaceuticals, Inc. (ABOS) had Shareholders' Equity of $57.26 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-12
- 2026-06-30: Stockholders' Equity Attributable to Parent $57.26M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $87.48M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $70.43M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $93.17M.
| Period end | Stockholders' Equity Attributable to Parent |
|---|---|
| 2026-06-30 | $57.26M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $87.48M 10-Q · filed 2026-08-12 |
| 2025-12-31 | $70.43M 10-Q · filed 2026-08-12 |
| 2025-09-30 | $93.17M 10-Q · filed 2025-11-12 |
| 2025-06-30 | $117.08M 10-Q · filed 2026-08-12 |
| 2025-03-31 | $155.52M 10-Q · filed 2026-08-12 |
| 2024-12-31 | $181.82M 10-Q · filed 2026-08-12 |
| 2024-09-30 | $217.20M 10-Q · filed 2025-11-12 |
| 2024-06-30 | $243.95M 10-Q · filed 2025-11-12 |
| 2024-03-31 | $262.03M 10-Q · filed 2025-08-12 |
| 2023-12-31 | $266.97M 10-K · filed 2026-03-26 |
| 2023-09-30 | $280.27M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $168.87M 10-Q · filed 2024-11-12 |
| 2023-03-31 | $179.09M 10-Q · filed 2024-08-13 |
| 2022-12-31 | $188.78M 10-K · filed 2025-03-27 |
| 2022-09-30 | $196.65M 10-Q · filed 2023-11-13 |
| 2022-06-30 | $206.52M 10-Q · filed 2023-11-13 |
| 2022-03-31 | $216.09M 10-Q · filed 2023-08-08 |
| 2021-12-31 | $225.18M 10-K · filed 2024-03-26 |
| 2021-09-30 | $233.36M 10-Q · filed 2022-11-14 |
| 2021-06-30 | -$106.08M 10-Q · filed 2022-11-14 |
| 2021-03-31 | -$45.46M 10-Q · filed 2022-08-15 |
| 2020-12-31 | -$18.59M 10-K · filed 2023-03-27 |
| 2020-09-30 | -$17.87M 10-Q · filed 2021-11-15 |
| 2020-06-30 | -$15.42M 10-Q · filed 2021-11-15 |
| 2020-03-31 | -$13.43M 10-Q · filed 2021-08-16 |
| 2019-12-31 | -$11.42M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |